Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis

BACKGROUND: Loss of response to infliximab or adalimumab in ulcerative colitis occurs frequently, and dose escalation may aid in regaining clinical benefit. This study aimed to systematically assess the annual loss of response and dose escalation rates for infliximab and adalimumab in ulcerative col...

Descripción completa

Detalles Bibliográficos
Autores principales: Savelkoul, Edo H J, Thomas, Pepijn W A, Derikx, Lauranne A A P, den Broeder, Nathan, Römkens, Tessa E H, Hoentjen, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547237/
https://www.ncbi.nlm.nih.gov/pubmed/36318229
http://dx.doi.org/10.1093/ibd/izac200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547237/
https://www.ncbi.nlm.nih.gov/pubmed/36318229
http://dx.doi.org/10.1093/ibd/izac200

Ejemplares similares